Pfizer PFE Long Weekly and MonthlyBuy Feb-24-23 43.5 Calls @ 0.1 Limit to Open (Weekly)
Buy Mar-24-23 47 Calls @ 0.11 Limit to Open (Monthly (W))
PFE trade ideas
$PFE - Over done? #PFESo #pfizer has been under relentless selling pressure. Is it over done? Let's look at a few things.
1. Every down turn saw an average of -24.46% peak to trough.
2. Stock V- bottomed after that.
3. Currently stock down -27.27% from its recent peak.
4. price at 100% fib extension
5. RSI same as covid low!
Looks a little overdone to me. What do you think?
PFE ready to fallAfter 9 consecutive weeks of higher lows, NYSE:PFE has broken down.
The chart has been streaky all year: Slow but steady marches downward from January to March, then July to October.
Honestly just looks like it's overdue for a fall, maybe hitting 38 by mid-March 2023.
PFE Screams `fff FED BUY ME NOW`A strong support and a nice bullish divergence.
Great fundamentals and great value.
If it is not gonna bounce from here lower fib support 37.21 USD is my all in price to enter.
First target in 3 to 4 months is 54.35 USD
I would stop below 37
Possible Head & Shoulders patternThe head and shoulders pattern forms when a stock's price rises to a peak and then declines back to the base of the prior up-move. Then, the price rises above the previous peak to form the "head" and then declines back to the original base. Finally, the stock price peaks again at about the level of the first peak of the formation before falling back down.
Bye from bottom possible side trendIdea:
Repulsion from 42.64 level
SL < 42.49
Buy - current price
Technicals:
- Con: Fallen trend
Financials:
- Pro: Growing Gross Margin
- Pro: Low debt to eq.
- Pro: Low P/E
- Pro: RoE is high enough
Will PFE do rebounce ?Harmonic BAT pattern.
Just to practice my analysis.
The pattern will cancel if the price drop below 41.54.
$PFE - Could see a bounce#PFE could see a double bottom bounce. If the price can break above $44.50 it could reach to $47 near term.
Target 1 - $45
Target 1 - $47
Target 2 - $51
——
Trade is done when it hit one of the target or stop loss is hit.
Disclaimer: Trading note. Not an investment advice.
PFE Call This week's selling (because of earnings) is a great chance to load up.
Might be some resistance around $48 but looks solid.
Pfizer 20% BounceTrading plan:
1. Wait until CM_Ultimater_MA_MFT_V2 indicates a reversal of secondary daily trend. This indication will be confirmed by change of the color of MA from red to green. Primary trend is still bearish until confirmed to be bullish.
2. CM_Williams_Vix_Fix at local daily bottom which can be seen as a confirmation of the reversal secondary bearish trend which started on December 29, 2022.
3. WT_LB is below oversold band which is also on daily timeframe is indicating a secondary trend reversal.
4. Resistance should a price ceiling of the bearish channel at $50-$52.
Implications:
1. Since CM_Ultimater_MA_MFT_V2 is lagging indicator there is a trade off between confirmation of the trend reversal and return rate of the trade. Therefore it could be prudent to start accumulating the position before we see a confirmation of the trend reversal by this MA.
2. This is post earnings period and Federal hike announcements/meetings have already passed. So volatility should be lower.
3. Of course this trading plan has worked out 100% in the last 8 times (of course there is an element of data mining) but trade should be done cautiously.
4. Stop loss would be if we start consolidating below $41-$40.5
Reckon it does not contract to the rationale I was trying to stick to:
- Identify a trend reversal (either primary of secondary on daily and weekly timeframes)
- Get into the position after considering different tools of confirmation and setting a stop loss.
- Ride the trend until there is a sign of trend reversal (either primary of secondary on daily and weekly timeframes) and try to get it confirmed.
- Close the position.
Please enjoy and if you have any further insights please share
Many thanks to the Community contributors (ChrisMoody and LazyBear). The tools they have assembled are of significant avail to all.
PFIZER (PFE) 6M Trading Analisys (TA)6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to $43, heading down to test the 100 days MA signal, at this moment there is a probability for the price to bounce up before continuing its way down to test the 100 MA signal, which is the optimistic approach, but remember "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy".
Today this ticker has a Volume of 5.297M with a Market Cap of 246B.
This Company PAYS DIVIDENDS TO SHAREHOLDERS
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Good Luck!
Gráfico de 6M, ( PFE ), al 6 de febrero de 2023, las señales en MACD se han estado moviendo constantemente hacia el NE, luego de cruzarse por debajo del histograma en julio de 2012; En julio de 2021, alcanzó su ATH (Mayor Precio Histórico); La señal RSI rebotó sobre 70 y ahora se dirige al SE para probar la señal de 50, luego de rebotar ahi en enero de 2020; El precio ha estado cayendo constantemente desde el ATH, de $60 a $43, bajando para probar la señal de 100 días MA, en este momento existe la probabilidad de que el precio rebote antes de continuar su camino hacia abajo para probar la señal de 100 MA, que es el enfoque optimista, pero recuerda: "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a tener razón nueve de cada diez veces. Descubrí que cuando el mercado está cayendo y compras fondos sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar".
Hoy este ticker tiene un Volumen de 5.297M con una Capitalización de Mercado de 246B.
Esta Empresa PAGA DIVIDENDOS A LOS ACCIONISTAS
Pfizer Inc. es una compañía biofarmacéutica global basada en la investigación. Se dedica al descubrimiento, desarrollo, fabricación, comercialización, venta y distribución de productos biofarmacéuticos en todo el mundo. La firma trabaja en mercados desarrollados y emergentes para promover el bienestar, la prevención, los tratamientos y las curas que desafían las enfermedades más temidas. La empresa fue fundada por Charles Pfizer Sr. y Charles Erhart en 1849 y tiene su sede en Nueva York, NY.
¡Buena suerte!
“I believe in analysis and not forecasting.” / "Creo en el análisis y no en el pronóstico".
REMEMBER : I am not a financial adviser nor is any content in this article presented as financial advice. The information provided in this blog post and any other posts that I make, and any accompanying material is for informational purposes only. It should not be considered financial or investment advice of any kind. One should consult with a financial or investment professional to determine what may be best for your individual needs. RECUERDE : No soy un asesor financiero y el contenido de este artículo no se presenta como asesoramiento financiero. La información provista en esta publicación de blog y cualquier otra publicación que haga y cualquier material que la acompaña es solo para fines informativos. No debe considerarse asesoramiento financiero o de inversión de ningún tipo. Se debe consultar con un profesional financiero o de inversiones para determinar qué es lo mejor para sus necesidades individuales.
PFE SqueezeMACD crossover, oversold RSI at 33, Strat Squeeze underway, 121 uptrend, touching the 9 EMA, if pokes through it will go to the 20 EMA, Red on D,Q; Green on 4H,W,M
$PFE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $PFE after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 100%.
PFERSI , MFI, And CCI Oversold.
Bounced around October lows.
Fib levels are ATH + 2009 lows
Stop loss 42$
Target area 48$ gap close..
This isn't your favorite tech stock that goes straight up so don't expect a rocket move.
Last 15% move from October lows took a month in a half out so grab some time
.
PFE into major SupportPfizer may provide a great risk to reward setup. Multi factor trade setup on pfizer likely sees a technical bounce. Keep in mind markets are weak.
earnings estimateas pandemic is slowering and chinese lockdown vix is going down stocks like pie healthcare can come down from their highs
Pharmaceutical Reversal?NYSE:PFE NYSE:ABBV will be on my watchlist next week.
Let's start with Pfizer first.
Pfizer has been down since mid of December 2022.
And now it is on interesting area (see on the chart)
In my view, area of $ 42.74 to $ 43.52 will be critical.
Next week Pivot Point will be at $ 44.24, if the price can stand above its weekly Pivot Point then a potential reversal may occur.
If we look at the weekly chart, EMA200 Weekly has been survived by the last downfall of PFE on October 2022.
MACD have shown a small bullish divergence.
Maybe an Earning Report can boost NYSE:PFE chart for next week.
Let's see.
$PFE - Oversold. Possible seller exhaustion#Pfizer has been oversold for some time. Today's gap down on UBS downgrade could be the seller exhaustion and potential bounce to come.
Target 1 - $46.5
Target 2 - $47.67
Target 3 - $51
Long term - $60
Risk - fall to $41.
——
Trade is done when it hit one of the target or stop loss is hit.
Disclaimer: Trading note. Not an investment advice.
$PFE: Interesting juncture here...Pfizer has a curious setup where both an uptrend or down trend could trigger next, depending on which extreme of last week's range is crossed first.
As per the chart, you can go long on a break of last week's high or short on a break of last week's low, with stops as depicted on chart. Targets may be subject to updates, if price action forms larger consolidation patterns in the direction of the trade and the initial entry isn't stopped. Odds of the trade working and making some progress in the next week are big if the trade is triggered, you could secure some gains by Friday close, if the target or the stop aren't hit, or just exit the trade altogether to revisit it next week, if continuation occurs.
Best of luck!
Ivan Labrie.
Potential 2-1-2 daily setupsPFE - failed 2u-1 on the daily, looking for more downside tomorrow. Put Trigger below 44.83. Put SL/Call trigger set at 45.32
JNJ - has a 2-1- on the daily. Feeling neutral but would prefer downside on this play. Call trigger above 169.62, Put trigger below 167.50. JNJ has earnings report tomorrow so be careful trading this one. (SL for call and put trigger is the other trigger)
HTHT - failed 2u-1 on the daily. Big gap to the downside on the daily. Only looking at puts below 48.06. SL above 48.95
PFE | Good Starter Position Entry | LONGPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE set back a good opportunityWe think the current setback provides a nice opportunity to buy some PFE with a nice dividend and decent ROE, for a move back into the low-to-mid fifties.
